Tim Garnett

Tim Garnett serves as the Chairman of Ophirex, Inc. since May 2021, and holds the position of Board Member at MapLight Therapeutics, Inc. Tim became an Equity Partner at Recode Ventures in April 2024 and has been an Advisor at Lindus Health, Biolojic Design, Ltd., Ukko, and Xentria, Inc. since 2024, 2021, 2021, and 2024 respectively. Additionally, Tim Garnett is a member of the Advisory Panel at Cambridge Innovation Capital since May 2021 and served as a Board Member at Carmot Therapeutics, Inc. from March 2022 to March 2024. Prior to these roles, Tim Garnett spent over two decades at Eli Lilly and Company, culminating in the role of Chief Medical Officer and Senior Vice President, overseeing various functions including Regulatory Affairs and Clinical Pharmacology. Tim Garnett holds a Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from St George's, University of London, awarded between 1979 and 1984.